Related Experiment Video

Updated: Jun 13, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Pazopanib: Clinical development of a potent anti-angiogenic drug

Fabio A B Schutz1, Toni K Choueiri, Cora N Sternberg

  • 1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Critical Reviews in Oncology/Hematology
|May 12, 2010
PubMed

Insights

Pazopanib, a tyrosine kinase inhibitor, effectively targets tumor growth and angiogenesis. Clinical trials show its efficacy in various cancers, including renal cell carcinoma, with manageable side effects.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI).
  • It inhibits key proteins involved in angiogenesis, tumor growth, and cell survival, including VEGFR and PDGFR.
  • Pazopanib has demonstrated in vitro and in vivo anti-tumor activity.

Purpose of the Study:

  • To review the clinical activity and safety of pazopanib.
  • To highlight its efficacy across various cancer types.
  • To discuss its role in treating advanced malignancies.

Main Methods:

  • Review of preclinical data and clinical trial results.
  • Analysis of pazopanib's mechanism of action.
  • Evaluation of safety profiles and efficacy in different tumor types.

Main Results:

  • Pazopanib is well-tolerated, with common side effects including hypertension, fatigue, and gastrointestinal issues.
  • Significant improvement in progression-free survival was observed in metastatic renal cell cancer (RCC) patients.
  • Demonstrated clinical activity in renal cell cancer, breast cancer, soft tissue sarcoma, thyroid cancer, hepatocellular cancer, and cervical cancer.
  • Combination therapy with lapatinib showed enhanced efficacy in metastatic breast cancer.

Conclusions:

  • Pazopanib is an effective targeted therapy for multiple cancer types.
  • Its favorable safety profile supports its use in clinical practice.
  • Ongoing trials continue to explore pazopanib's therapeutic potential.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...